Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line

Saudi Medical Journal

Volumn 30, Issue 1, 2009, Pages 35-40

  Yang, Jun Xia ^a   Luo, Ying ^a   Qiu, Hong Mei ^a   Tang, Wei Xue ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MITOMYCIN; PLATINUM COMPLEX; VINCRISTINE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN;

EID: 62849115075     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57: 1229-1235.
2. Fink D, Howell SB. How does cisplatin kill cells? In: Kelland LR, Farrell N, editors. Platinum-based drugs in cancer therapy. 7th ed. Totawa (NJ): Humana Press Inc; 2000. p. 149-167.
3. Akiyama S, Chen Z, Sumizawa T, Furukawa T. Resistance to cisplatin. Anticancer Drug Des 1999; 14: 143-151.
4. Martelli L, Di Mario F, Ragazzi E, Apostoli P, Leone R, Perego P, et al. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 2006; 72: 693-700.
5. Byun SS, Kim SW, Choi H, Lee C, Lee E. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005; 95: 1086-1090.
6. Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: Relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 2004; 39: 1196-1201.
7. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997; 70: 551-555.
8. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997; 57: 850-856.
9. Brenes O, Arce F, Gätjens-Boniche O, Días C. Characterization of cell death events induced by enti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. Biomed Pharmacother 2007; 61: 347-355.
10. Llovet JM, Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol 2003; 38 Suppl 1: S136-S149.
11. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-1897.
12. Okamura M, Hashimoto K, Shimada J, Sakagami H. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines. Anticancer Res 2004; 24: 655-661.
13. Wang JB. Establishment and some characteristics of a hepatoma cell line (QGY-7703). Zhonghua Zhong Liu Za Zhi 1981; 3: 241-244. Chinese.
14. Zhenqiang S, Junzheng W. The cell culture. Si'an (CN): World Publishing Corporation; 1996. p. 136-137.
15. Li JP, Bian DH. Derivation and biological characterization of multidrug resistant human ovarian cell line. Prog Obstet Gynecol 2001; 10: 13-16.
16. Huang W, Li L, Tang DP, Chen XQ, Li DR. Establishment of a new cisplatin-resistant cell line and studying of its mechanism, characterization of drug-resistance. China Oncology 1998; 8: 187-189.
17. Zhang HX, Wang ZM, Guo WP, Wang YQ, Liu Y, Guan Y. Establishment of human multidrug-resistant hepato cellular carcinoma cell line (7721/ Adm). Journal of Nanjing Medical University 2000; 21: 425-429.
18. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
19. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000; 35: 75-93.
20. Gately DP, Howell SB. Cellular accumulation on the anticancer agent cisplatin: A review. Br J Cancer 1993; 67: 1171-1176.
21. Zhan MC, Liu XY, Cai P, Xu GW. Mechanism of Resistance of Human Cell Line A549DDP to Cisplatin. Chinese Journal of Clinical Oncology 1998; 25: 726-728.
22. Liang XJ, Yin JJ, Zhou JW, Wang PC, Taylor B, Cardarelli C, et al. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Exp Cell Res 2004; 293: 283-291.
23. Katragadda S, Budda B, Anand BS, Mitra AK. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv 2005; 2: 683-705.
24. Chen J, Yang R, Liu F. Establishment of cisplatin-induced resistant human ovrian epithelial cancer cell line 3AO/CDDP and experimental study on its resistant mechanisms. Prog Obstet Gynecol 2000; 9: 178-181.
25. Fujii R, Mutoh M, Niwr K, Yamada K, Aikou T, Nakagawa M. An active efflux system for cisplatin in cisplatin- resistant human KB cells. Jpn J Cancer Res 1994; 85: 426-433.
26. Townsend DM, Tew KD. The role of glutathione-s transferase in anticancer drug resistance. Oncogen 2003; 22: 7369-375.